"Hyaluronoglucosaminidase"[nm] - Search Results

Year	Number of Results
1945	5
1946	16
1947	26
1948	61
1949	86
1950	156
1951	167
1952	257
1953	229
1954	249
1955	175
1956	173
1957	128
1958	118
1959	89
1960	89
1961	74
1962	88
1963	154
1964	165
1965	137
1966	128
1967	150
1968	186
1969	168
1970	186
1971	185
1972	192
1973	208
1974	217
1975	161
1976	118
1977	113
1978	92
1979	113
1980	112
1981	82
1982	104
1983	94
1984	80
1985	89
1986	67
1987	56
1988	58
1989	59
1990	81
1991	58
1992	70
1993	56
1994	78
1995	85
1996	79
1997	86
1998	86
1999	74
2000	88
2001	84
2002	89
2003	92
2004	91
2005	115
2006	98
2007	111
2008	110
2009	119
2010	120
2011	119
2012	121
2013	135
2014	138
2015	140
2016	133
2017	122
2018	137
2019	170
2020	160
2021	163
2022	137
2023	93
2024	72

1

Fundamental considerations for the use of hyaluronidase, an enzyme for degrading HA fillers.

Hong GW, Yi KH. Hong GW, et al. Skin Res Technol. 2024 Jul;30(7):e13839. doi: 10.1111/srt.13839. Skin Res Technol. 2024. PMID: 38951943 Free PMC article. No abstract available.

2

[Pharmacological properties and clinical development overview of pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination) (PHESGO^® combination for ‍subcutaneous injection MA, IN)].

Sakaeda M, Kotani N, Yoneya T, Zheng Y, Habara Y. Sakaeda M, et al. Nihon Yakurigaku Zasshi. 2024;159(4):241-253. doi: 10.1254/fpj.24022. Nihon Yakurigaku Zasshi. 2024. PMID: 38945908 Review. Japanese.

3

Hyaluronidase inhibitor delphinidin inhibits cancer metastasis.

McGuire J, Taguchi T, Tombline G, Paige V, Janelsins M, Gilmore N, Seluanov A, Gorbunova V. McGuire J, et al. Sci Rep. 2024 Jun 28;14(1):14958. doi: 10.1038/s41598-024-64924-6. Sci Rep. 2024. PMID: 38942920 Free PMC article.

4

Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants.

Li Z, Nagy A, Lindner D, Duff K, Garcia E, Ay H, Rondon JC, Yel L. Li Z, et al. J Clin Immunol. 2024 Jun 19;44(7):148. doi: 10.1007/s10875-024-01742-5. J Clin Immunol. 2024. PMID: 38896141 Free PMC article. Clinical Trial.

5

Acyclovir extravasation in a newborn: a case report.

Shamel S, Zarkesh MR. Shamel S, et al. J Med Case Rep. 2024 Jun 7;18(1):271. doi: 10.1186/s13256-024-04585-1. J Med Case Rep. 2024. PMID: 38845030 Free PMC article.

6

OGA mutant aberrantly hydrolyzes O-GlcNAc modification from PDLIM7 to modulate p53 and cytoskeleton in promoting cancer cell malignancy.

Hu CW, Wang A, Fan D, Worth M, Chen Z, Huang J, Xie J, Macdonald J, Li L, Jiang J. Hu CW, et al. Proc Natl Acad Sci U S A. 2024 Jun 11;121(24):e2320867121. doi: 10.1073/pnas.2320867121. Epub 2024 Jun 5. Proc Natl Acad Sci U S A. 2024. PMID: 38838015

7

Optimization and mechanisms of proteolytic enzyme immobilization onto large-pore mesoporous silica nanoparticles: Enhanced tumor penetration.

Qiu N, Lv QY, Li CL, Song X, Wang YQ, Chen J, Cui HF. Qiu N, et al. Int J Biol Macromol. 2024 Jun;271(Pt 1):132626. doi: 10.1016/j.ijbiomac.2024.132626. Epub 2024 May 23. Int J Biol Macromol. 2024. PMID: 38795893

8

Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials.

Arias-Lorza AM, Costello JR, Hingorani SR, Von Hoff DD, Korn RL, Raghunand N. Arias-Lorza AM, et al. Sci Rep. 2024 May 21;14(1):11570. doi: 10.1038/s41598-024-62470-9. Sci Rep. 2024. PMID: 38773189 Free PMC article.

9

Targeting starvation therapy for diabetic bacterial infections with endogenous enzyme-triggered hyaluronan-modified nanozymes in the infection microenvironment.

Liu Y, Zhang X, Yang S, Guo Q, Zhang Y, Wang Z, Xu S, Qiao D, Ma M, Zheng P, Zhu W, Pan Q. Liu Y, et al. Int J Biol Macromol. 2024 Jun;270(Pt 1):132277. doi: 10.1016/j.ijbiomac.2024.132277. Epub 2024 May 10. Int J Biol Macromol. 2024. PMID: 38735611

10

Isolation, Characterization, Genome Annotation, and Evaluation of Hyaluronidase Inhibitory Activity in Secondary Metabolites of Brevibacillus sp. JNUCC 41: A Comprehensive Analysis through Molecular Docking and Molecular Dynamics Simulation.

Xu Y, Liang X, Hyun CG. Xu Y, et al. Int J Mol Sci. 2024 Apr 23;25(9):4611. doi: 10.3390/ijms25094611. Int J Mol Sci. 2024. PMID: 38731830 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

9,047 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

9,047 results

Results by year